Our in vivo results lend support to the idea that the primary effect of Hh inhibition in pancreatic cancer treatment is due to the inhibition of Hh pathway activity in the stromal cells, although we also observe a mild initial reduction of GLI1 levels in tumor cells. The gene discussed is GLI1; the disease is pancreatic neoplasm.